Sign in Subscribe
Medical equipment industry

Synovis Life Technologies Appoints David Buche as Chief Operating Officer

Strategic Insights

— 2 min read

Synovis Life Technologies has announced the appointment of David Buche as vice president of Synovis Life Technologies and chief operating officer of the Synovis Surgical Innovations division. In this new role, Buche will oversee all business aspects of the division, including sales, marketing, and operations. He reports directly to Karen Gilles Larson, president and chief executive officer of Synovis Life Technologies.

The decision to expand the executive team comes as the company continues to experience significant growth, with revenue in the surgical business increasing by 63 percent from fiscal 2001 to 2003. Despite a slower growth rate in the current fiscal year, Synovis Life Technologies is optimistic about future opportunities in new markets and in gastric bypass surgery. The company's top-selling product, Peri-Strips, has seen significant growth in recent years, driven by applications in gastric bypass surgery to treat morbid obesity. Synovis has recently received FDA marketing clearance for additional Peri-Strips applications, creating further revenue opportunities.

Karen Gilles Larson expressed her confidence in Buche's leadership abilities, stating, "David and I have worked closely together since his appointment to vice president in January 1998. He is a tenacious, creative and tireless leader with a broad knowledge of our surgical business." Prior to his appointment as vice president of marketing and sales in January 1998, Buche held various marketing and sales leadership positions at Synovis and Spectranetics Corporation.

Key Takeaways:

  • Synovis Life Technologies has appointed David Buche as vice president of Synovis Life Technologies and chief operating officer of the Synovis Surgical Innovations division.
  • Buche will oversee all business aspects of the division, including sales, marketing, and operations.
  • The company has experienced significant growth, with revenue in the surgical business increasing by 63% from fiscal 2001 to 2003.
  • Synovis has recently received FDA marketing clearance for additional Peri-Strips applications, creating further revenue opportunities.
  • Buche has a broad knowledge of the surgical business and has held various leadership positions at Synovis and Spectranetics Corporation.
  • The decision to expand the executive team is part of Synovis' plan to manage its business effectively and capitalize on future opportunities.

Statistics:

  • Revenue in the surgical business increased by 63 percent from fiscal 2001 to 2003.
  • Peri-Strips revenue growth has been driven by applications in gastric bypass surgery to treat morbid obesity.
  • Synovis has received FDA marketing clearance for additional Peri-Strips applications.

Sources:

  • [Synovis Life Technologies press release, undated]
  • [Synovis Surgical Innovations website, http://www.synovissurgical.com/]
  • [Synovis Life Technologies website, http://www.synovislife.com/]
  • [Private Securities Litigation Reform Act of 1995]

Read more